https://www.selleckchem.com/pr....oducts/ozanimod-rpc1
Neutrophils play a controversial role in tumor development. The function of programmed cell death-1 ligand (PD-L1 ) neutrophils, however, may inhibit the cytotoxicity of anti-tumor immunity. In this study, we elucidate the stimulators of PD-L1 neutrophils in tumor microenvironment (TME) and explore the optimal combination to enhance the effect of lenvatinib by inhibiting PD-L1 neutrophils in hepatocellular carcinoma. Neutrophil infiltration after lenvatinib treatment was examined with RNA sequencing and multicolor flow cytometr